Fact Meets Function

Research demonstrates that SIRT7, a histone deacetylase, protects against abdominal aortic aneurysm (AAA) formation by deacetylating serum response factor (SRF), which maintains vascular smooth muscle cell contractile function. SIRT7 is markedly downregulated in human AAA tissues, and its deficiency accelerates aneurysm progression through enhanced SRF degradation and pathological smooth muscle phenotype switching. Critically, the study shows that nicotinamide mononucleotide (NMN), a NAD+ precursor, pharmacologically activates SIRT7 and attenuates aortic dilation in animal models, suggesting NMN supplementation as a novel therapeutic strategy for AAA prevention.

This in vitro study demonstrates that metformin suppresses cancer cell migration in KEAP1-deficient lung adenocarcinoma cells primarily through NAD+ depletion rather than AMPK activation. The researchers showed that supplementing with nicotinamide mononucleotide (NMN) restored cellular motility in metformin-treated cells, directly implicating NAD+ availability as the mechanistic driver. The finding has significant implications for practitioners considering NAD+-boosting supplements alongside conventional cancer therapies or metabolic interventions.

Researchers developed pH-responsive chitosan nanoparticles encapsulating NMN to overcome bioavailability and rapid clearance limitations in acute kidney injury treatment. The delivery system activates SIRT1 signaling, suppresses NF-κB inflammation, reduces oxidative stress, and promotes tubular repair in kidney injury models. This represents a significant advance in NMN formulation technology that directly addresses a core challenge in oral peptide/supplement delivery: achieving sustained therapeutic effect with reduced dosing frequency.

This research article presents a novel two-photon microscopy protocol for real-time visualization of NAD+ metabolism in brain endothelial cells in living mice. The study demonstrates technical methods to monitor how oral NMN (nicotinamide mononucleotide) delivery affects cerebrovascular NAD+ biosensor fluorescence, providing mechanistic evidence of NMN’s bioavailability and metabolic impact at the blood-brain barrier. This validates in vivo NAD+ pathway engagement as a measurable biomarker for oral peptide and nutrient supplements targeting neurometabolism.

This peer-reviewed analysis examines NAD+ supplementation through combined literature review and mathematical modeling, confirming that oral NAD+ precursors like NMN and nicotinamide riboside can elevate circulating NAD+ levels but yield variable clinical outcomes. The study reveals NAD+ responses follow nonlinear dose-response patterns influenced by age, metabolic state, and administration route, with complex feedback mechanisms and biological saturation limits. The authors caution against oversimplified interpretation of current evidence and call for rigorously designed clinical trials to establish safe and effective therapeutic protocols. This directly impacts practitioner confidence in NMN dosing and patient outcome expectations.

NMN supplementation at high doses demonstrated anti-tumor efficacy comparable to PD-1 checkpoint inhibitors in a murine mesothelioma model by reprogramming tumor-associated macrophages toward a pro-inflammatory M1 phenotype rather than enhancing T cell or NK cell responses. This represents a novel immunotherapy mechanism distinct from current checkpoint blockade strategies. The findings suggest NMN may offer an alternative or complementary cancer immunotherapy approach by modulating innate immunity through macrophage phenotype shifting.

Researchers developed a sustained-release microsphere formulation of NMN that significantly alleviates chemotherapy-induced myelosuppression by restoring bone marrow function and peripheral blood cell counts in animal models. The mechanism involves activation of the PI3K-PTEN-AKT-Bcl-2 signaling pathway, which protects hematopoietic stem cells from chemotherapy-induced apoptosis and promotes cytokine secretion. This formulation approach addresses a major clinical problem in cancer patients—bone marrow suppression—and represents a promising therapeutic strategy for chemotherapy side-effect management.

NMN supplementation restored hepatic NAD+ levels in alcohol-fed mice, which attenuated liver steatosis, inflammation, and oxidative stress through restoration of the Hamp iron-regulation pathway. The mechanism involves C/EBPα-mediated transcriptional control of Hamp expression, linking NAD+ metabolism to iron homeostasis and lipid metabolism. This identifies NMN as a targeted dietary therapeutic for alcohol-associated liver disease (ALD) with a well-characterized molecular pathway, offering practitioners a science-backed rationale for recommending NMN to patients with metabolic liver dysfunction.

This research demonstrates that biological sex differences in NAD+ biosynthesis pathways significantly influence susceptibility to ischemia-reperfusion-induced acute kidney injury (AKI). The study identifies sex-dimorphic NAD+ metabolism as a key molecular mechanism underlying sex-biased AKI outcomes. For practitioners, this suggests NAD+-supporting interventions like NMN may have sex-specific efficacy profiles in kidney protection and warrant sex-stratified clinical consideration when addressing AKI prevention.

Researchers developed lactoferrin-modified lipid nanoparticles (LNPs) to deliver NMN across the blood-brain barrier, achieving 62% BBB permeability—significantly higher than unmodified NMN. The formulation showed enhanced pharmacokinetics and selective brain tissue accumulation in rat models without cytotoxicity. This advancement addresses NMN’s poor BBB penetration, a key limitation for neurotherapeutic applications in neurodegenerative disease treatment.

This preclinical study examined whether NMN improves sleep and circadian rhythms in brain-specific SIRT1 knockout and wild-type mice. Both acute (10-day IP injection) and chronic (2-month oral) NMN treatment failed to improve sleep duration or quality in middle-aged mice. The researchers suggest NMN’s reported clinical benefits for sleep in elderly populations may work indirectly through improvements in muscle function and energy metabolism rather than direct sleep mechanisms.